| Notice of Special Interest (NOSI)—Administrative Supplements for Lyme Disease and other Tickborne Illnesses - NOT-AI-22-048 |
Supp
|
April 27, 2022 |
May 24, 2022 |
| Shared Personal Protective Equipment (PPE) Resources (S10 Clinical Trial Not Allowed)- PAR-21-257 |
S10
|
June 03, 2021 |
May 25, 2022 |
| Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) Collaborative Research Centers (CRCs) (U54, Basic Experimental Studies Involving Humans Allowed)- RFA-NS-22-019 |
U54
|
February 15, 2022 |
May 25, 2022 |
| Data Management and Coordinating Center (DMCC) for the Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) Collaborative Research Centers (CRC) (U24 Basic Experimental Studies with Humans Required)- RFA-NS-22-020 |
U24
|
February 15, 2022 |
May 25, 2022 |
| Notice of Special Interest (NOSI)—Administrative Supplements for NIAID Regional Biocontainment Laboratories (RBL) and other NIH Grantees Conducting Research at RBL-affiliated Sites- NOT-AI-22-049 |
Supp
|
May 04, 2022 |
June 01, 2022 |
| Partnerships for Rapid Diagnostics and Phenotypic Antibacterial Susceptibility Testing for Bacteremia or Hospital Acquired Pneumonia (R01 Clinical Trial Not Allowed)- RFA-AI-22-010 |
R01
|
February 23, 2022 |
June 02, 2022 |
| Asthma and Allergic Diseases Cooperative Research Centers (U19 Clinical Trial Optional)- RFA-AI-21-079 |
U19
|
December 23, 2021 |
June 04, 2022 |
| Biomarker Signatures of TB Infection in Young Children With and Without HIV (R01 Clinical Trial Not Allowed)- RFA-AI-22-015 |
R01
|
February 09, 2022 |
June 09, 2022 |
| Lasker Clinical Research Scholars Program (Si2/R00 Clinical Trial Optional)- PAR-22-078 |
Si2/R00
|
January 26, 2022 |
June 25, 2022 |
| Immune Drivers of Autoimmune Disease (IDAD) (U01 Clinical Trial Not Allowed)- RFA-AI-22-012 |
U01
|
February 24, 2022 |
July 02, 2022 |
| Development and Optimization of Next-Generation Immunological Assays to Support Influenza Clinical Studies and Trials (UH2/UH3 Clinical Trial Not Allowed)- RFA-AI-22-020 |
UH2/UH3
|
April 05, 2022 |
July 02, 2022 |
| Notice of Special Interest—Administrative Supplements to Advance Precision Medicine Using the All of Us Research Programs Data- NOT-PM-22-002 |
Supp
|
May 20, 2022 |
July 06, 2022 |
| Improved Drug Susceptibility Testing (DST) for Tuberculosis (R01 Clinical Trial Not Allowed)- RFA-AI-22-016 |
R01
|
March 02, 2022 |
July 09, 2022 |
| NIH Science Education Partnership Award (SEPA) (R25 - Clinical Trial Not Allowed)- PAR-20-153 |
R25
|
April 08, 2022 |
July 14, 2022 |
| NIH Science Education Partnership Award (SEPA) (R25 - Clinical Trial Not Allowed)- PAR-20-153 |
|
March 30, 2020 |
July 14, 2022 |
| Limited Competition Emergency Awards—Shared Personal Protective Equipment Resources for COVID-19 Related Vaccine and Treatment Clinical Trials and Clinical Studies (S10 Clinical Trial Not Allowed)- PAR-21-276 |
S10
|
July 16, 2021 |
July 16, 2022 |
| Centers for AIDS Research (P30 Clinical Trial Not Allowed)- PAR-20-106 |
P30
|
February 03, 2020 |
July 29, 2022 |
| Developmental Centers for AIDS Research (P30 Clinical Trial Not Allowed)- PAR-20-107 |
P30
|
February 03, 2020 |
July 29, 2022 |
| Innovation for HIV Vaccine Discovery (R01 Clinical Trial Not Allowed)- PAR-20-158 |
R01
|
March 31, 2020 |
July 29, 2022 |
| Partnerships for the Development of Novel Therapeutics to Combat Select Antibiotic Resistant Bacteria and Fungi (R01 Clinical Trial Not Allowed)- RFA-AI-22-028 |
R01
|
April 05, 2022 |
July 30, 2022 |
| Development of HIV Broadly Neutralizing Antibody Susceptibility Assays (R61/R33 Clinical Trial Not Allowed)- RFA-AI-22-022 |
R61/R33
|
March 10, 2022 |
August 04, 2022 |
| Enhancing HIV Reservoir Susceptibility to Elimination (R01 Clinical Trial Not Allowed)- RFA-AI-22-025 |
R01
|
March 29, 2022 |
August 04, 2022 |
| Limited Interaction Targeted Epidemiology—Viral Suppression (LITE-VS) (UG3/UH3 Clinical Trial Optional)- RFA-AI-22-024 |
UG3/UH3
|
April 13, 2022 |
August 04, 2022 |
| International Research in Infectious Diseases (R01 Clinical Trial Not Allowed)- PAR-20-108 |
R01
|
February 04, 2020 |
August 20, 2022 |
| Getting To Zero—Understanding HIV Viral Suppression and Transmission in the United States (R01, Clinical Trial Optional)- PAR-20-036 |
R01
|
October 24, 2019 |
September 08, 2022 |
